Concomitant high-grade prostatic intraepithelial neoplasia is associated with good prognosis factors and oncologic outcome after radical prostatectomy.

Abstract

OBJECTIVES:

To assess correlations between concomitant high-grade prostatic intraepithelial neoplasia (HGPIN), pathological features and oncologic outcomes after radical prostatectomy (RP).

MATERIAL AND METHODS:

We prospectively collected a single-institution database of 2,351 patients who underwent RP between 1998 and 2011.

RESULTS:

1,272 (54.1%) patients had HGPIN on specimens. The mean follow-up was 28 months. Presence of HGPIN was significantly associated with a favorable preoperative risk status and with pathological factors of poor prognosis in RP specimens. Patients without HGPIN had a worse biochemical recurrence-free survival compared with those with HGPIN in RP specimen (log-rank test: p = 0.015). The 3-year RFS rate was 73.9% for the HGPIN group versus 67.2%. The absence of HGPIN was also significantly correlated with the use of androgen deprivation treatment during the follow-up (p < 0.001). In Cox multivariate analysis, taking into account the other prognostic pathological factors, HGPIN was not an independent predictive factor for PSA failure (p = 0.868).

CONCLUSION:

HGPIN is associated with factors of good prognosis but fails to show independent significance when classical pathological prognostic factors are taken into account.

• Authors: Alexandre Ingels, Guillaume Ploussard, Yves Allory, Claude Abbou, Alexandre de la Taille, Laurent Salomon
• Journal: Urologia internationalis (Urol Int) Vol. 92 Issue 3 Pg. 264-9 ( 2014) ISSN: 1423-0399 [Electronic] Switzerland
• PMID: 23919964 (Publication Type: Journal Article)
• Copyright: Copyright © 2013 S. Karger AG, Basel.

Chemical References

• Androgen Antagonists
• Antineoplastic Agents, Hormonal
• KLK3 protein, human
• Kallikreins
• Prostate-Specific Antigen

Topics

• Adenocarcinoma (blood, mortality, pathology, surgery)
• Adult
• Aged
• Aged, 80 and over
• Androgen Antagonists (therapeutic use)
• Antineoplastic Agents, Hormonal (therapeutic use)
• Chemotherapy, Adjuvant
• Databases, Factual
• Disease-Free Survival
• Humans
• Kallikreins (blood)
• Kaplan-Meier Estimate
• Male
• Middle Aged
• Multivariate Analysis
• Neoplasm Grading
• Proportional Hazards Models
• Prostate-Specific Antigen (blood)
• Prostatectomy (adverse effects, mortality)
• Prostatic Intraepithelial Neoplasia (blood, mortality, pathology, surgery)
• Prostatic Neoplasms (blood, mortality, pathology, surgery)
• Retrospective Studies
• Risk Factors
• Time Factors
• Treatment Outcome